Fig. 4From: Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutationForest plots of the meta-analysis for the prevalence of TERT promoter mutations in follicular thyroid carcinomas (a), Hürthle cell carcinoma (b), poorly differentiated carcinoma (c), and anaplastic carcinoma (d)Back to article page